A retrospective observational analysis of a cohort with HFpEF

  • Research type

    Research Study

  • Full title

    A retrospective observational analysis of a cohort with Heart Failure with Preserved Ejection Fraction from a BNP pathway clinic

  • IRAS ID

    262060

  • Contact name

    Kaushik Guha

  • Contact email

    kaushik.guha@porthosp.nhs.uk

  • Sponsor organisation

    Portsmouth Hospitals NHS Trust

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    0 years, 7 months, 1 days

  • Research summary

    Heart failure with preserved ejection fraction (HFpEF) is a complex condition with various causes that is not yet fully understood. Heart failure is a long-term condition where the heart is unable to pump enough blood to meet the demands of the body. Heart failure is then categorised based on ejection fraction, which is the percentage of how much blood the heart pumps out each beat. HFpEF is a form of heart failure were the heart still pumps >50% of its volume each heart beat. Most significantly there is no method of diagnosing or treating the condition. A recent project proposed non-invasive criteria using routinely collected data to predict the likelihood of HFpEF. This was termed H2FPEF and uses: weight, number of hypertensive medications prescribed, age, presence of atrial fibrillation, ventricular filling pressures and pulmonary hypertension. The main limitation of this study is the use of a single centre population from the Mayo clinic in Rochester, US. Another limitation is that the H2FPEF criterion consists of common conditions which could as a result overestimate HFpEF probability. Our aim is to test the H2FPEF criteria on previous data already held from heart failure clinic database at Queen Alexandra Hospital (QAH) in Portsmouth. Implications of our project if H2FPEF is proved to be accurate on our population is that it can be used in our Trust and other trusts. This would allow HFpEF to be identified quicker, at a reduced cost for the trust and reduced risk for the patient avoiding invasive investigations. On the other hand if H2FPEF is found not to be applicable to our population then further research would be required to find the ideal tool or method to identify HFpEF. A follow-up of patients is also proposed to monitor any long-term outcomes and how they respond to treatments.

  • REC name

    East of England - Cambridge East Research Ethics Committee

  • REC reference

    19/EE/0386

  • Date of REC Opinion

    6 Jan 2020

  • REC opinion

    Favourable Opinion